193 related articles for article (PubMed ID: 28231718)
1. Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy.
Bolourian A; Mojtahedi Z
Immunotherapy; 2017 Mar; 9(3):281-288. PubMed ID: 28231718
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
3. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
4. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
5. Cellular therapy of cancer with natural killer cells-where do we stand?
Klingemann HG
Cytotherapy; 2013 Oct; 15(10):1185-94. PubMed ID: 23768925
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
7. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-mediated immunosurveillance of human cancer.
Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
[TBL] [Abstract][Full Text] [Related]
9. NK cells to cure cancer.
Di Vito C; Mikulak J; Zaghi E; Pesce S; Marcenaro E; Mavilio D
Semin Immunol; 2019 Feb; 41():101272. PubMed ID: 31085114
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
12. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
14. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials.
Suen WC; Lee WY; Leung KT; Pan XH; Li G
Cancer Invest; 2018; 36(8):431-457. PubMed ID: 30325244
[TBL] [Abstract][Full Text] [Related]
16. NK cells and Immunotherapy.
Tian Z
Semin Immunol; 2017 Jun; 31():1-2. PubMed ID: 28985906
[No Abstract] [Full Text] [Related]
17. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
18. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
19. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
20. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.
Haeryfar SM
Arch Iran Med; 2008 Mar; 11(2):186-95. PubMed ID: 18298297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]